ARCHIVES

Mendelsohn Defends ImClone’s Actions And His Role In Development of C225

This article is from The Cancer Letter archive.

Vol. 28 No. 38 | October 18, 2002

Download PDF Visit The Full Archive

Related Articles

Increase In DCCR Grants May Not Be Possible Without Decreasing Quality, Committee Told

July 28, 1978

ODAC To Advise FDA on First Biosimilars Application Jan. 7

December 19, 2014

Surgical Oncologists Certification Asked By SSO Workshop

December 9, 1983

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

In Brief: Selection Of NCI Director Extended By Month; Fisher Named NSABP Scientific Director

March 17, 1995

Iniparib Plus Chemo Shows Benefit In Phase II Study

January 28, 2011